2020-11-18
Use of Chemotherapy and Androgen Signaling–targeted Inhibitors in Patients with Metastatic Prostate Cancer
Publication
Publication
European Urology : Official Journal of the European Association of Urology
The recent CARD study has shown that sequential use of androgen receptor (AR)-targeted therapies is associated with worse outcomes when compared with cabazitaxel chemotherapy. Here we argue that this accounts for the majority of patients previously treated with an AR-targeted agent.
| Additional Metadata | |
|---|---|
| doi.org/10.1016/j.eururo.2020.10.016, hdl.handle.net/1765/131691 | |
| European Urology : Official Journal of the European Association of Urology | |
| Organisation | Erasmus MC: University Medical Center Rotterdam |
|
de Wit, R., Tombal, B., & Freedland, S. (Stephen). (2020). Use of Chemotherapy and Androgen Signaling–targeted Inhibitors in Patients with Metastatic Prostate Cancer. European Urology : Official Journal of the European Association of Urology. doi:10.1016/j.eururo.2020.10.016 |
|